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Abstract
Background: Serum adipokines have roles in the development of arterial stiffness. Our aim was to investigate the
relationship of leptin and the surrogate marker carotid-femoral pulse wave velocity (cfPWV) in coronary artery
disease (CAD) patients.
Methods: Fasting blood samples were obtained from 105 CAD patients. cfPWV was measured with the
SphygmoCor system. A cfPWV > 10 m/s was defined as high arterial stiffness, and ≤ 10 m/s as low arterial stiffness.
Results: Thirty-seven patients (35.2 %) had high arterial stiffness, and had a higher percentage of diabetes (P = 0.001),
hypertension (P = 0.010), older age (P = 0.001), and higher systolic blood pressure (SBP) (P < 0.001), diastolic blood
pressure (DBP) (P = 0.021), pulse pressure (P = 0.014), and serum leptin level (P = 0.002) compared to patients with low
arterial stiffness. Serum leptin levels correlated with the number of angiographically documented stenotic coronary
artery vessels (P < 0.001). After adjusting for factors significantly associated with arterial stiffness, multivariate logistic
regression analysis showed that leptin (odds ratio = 1.026, 95 % confidence interval: 1.002–1.051, P = 0.037) was a
significant independent predictor of arterial stiffness.
Conclusions: Increasing serum concentration of leptin correlated positively with the total number of stenotic coronary
arteries, and serum leptin level may predict the development of arterial stiffness in CAD patients.
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Background
Arterial stiffness is one of the multiple characteristics of
cardiovascular disease (CVD), and the mechanisms of
arterial stiffness most often include abnormal regulation
of elastin fibers and collagen, re-organization of cellular
elements, and low-grade inflammation [1–3]. One meta-
analysis showed increased pooled relative risks for total
CV events, CV mortality, and all-cause mortality for
subjects with high versus low brachial-ankle pulse wave
velocity (PWV) [4]. PWV has been recognized as a non-
invasive method to access vascular function, and as the
gold standard surrogate marker of arterial wall function
and structure [5]. A systematic review showed that
aortic PWV is a strong predictor of future CV events
and all-cause mortality, and has a predictive value inde-
pendent of classical CV risk factors [6].
Studies have shown a relationship between CVD and
adipokines such as leptin, adiponectin, and resistin [7, 8].
Leptin was discovered in 1994, and is a 16-kDa product of
the obese gene mainly produced by white adipose tissue,
and is involved in a wide range of functions beyond fat
storage [9]. Classical effects of leptin include food intake
reduction and increased energy expenditure, and its levels
are directly associated with white adipose tissue [10].
Hyperleptinemia has been implicated in metabolic, in-
flammatory, and homeostatic factors involved in obesity,
hypertension (HTN), and CVD [11–13]. Leptin has been
associated with enhanced neointimal and medial thicken-
ing of injured carotid artery vascular walls, and stimulates
the renin-angiotensin-aldosterone system, the prolifera-
tion of vascular smooth muscle cells, endothelial oxidative
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stress, and the formation of reactive oxygen species, which
contributed to the development of aortic mechanical dys-
function and arterial stiffness [12, 14–16]. Increased PWV
had been shown to predict a greater risk of CV morbidity
and mortality in hypertensive and diabetic patients, but
the relationship of serum leptin and arterial stiffness in pa-
tients with coronary artery disease (CAD) is not clear.
Thus, the aim of this study was to examine the risk factors
contributing to arterial stiffness measured by PWV in an-
giographically diagnosed CAD patients, to examine the
correlation of serum leptin and carotid-femoral PWV, and
to observe the relationship between serum leptin and se-
verity of CAD (number of stenotic coronary arteries).
Methods
Patients
The Protection of the Human Subjects Institutional Re-
view Board of Tzu-Chi University and Hospital approved
this study. Between March and December 2012, 105
CAD patients (79 males and 26 females; CAD defined
as > 50 % stenosis in any segment by coronary angiog-
raphy) in a medical center in Hualien, eastern Taiwan
were enrolled in this study. Trained staff measured
blood pressure (BP) in the morning for all participants
using a standard mercury sphygmomanometer with ap-
propriate cuff size after the patients had been sitting for
at least 10 min. Systolic BP (SBP) and diastolic BP (DBP)
were taken at the points of appearance and disappear-
ance, respectively, of the Korotkoff sounds. SBP and
DBP were taken three times at 5 min intervals, and were
averaged for analysis. Pulse pressure was calculated by
subtracting DBP from SBP. HTN was defined as SBP ≥
140 mmHg, and/or DBP ≥ 90 mmHg, or prescription of
antihypertensive medication in the past 2 weeks. A per-
son was regarded as having diabetes mellitus (DM) if the
fasting plasma glucose was either 126 mg/dl or more, or
if he/she was using diabetes medications (oral or insulin)
[17]. Participants were excluded if they had an acute in-
fection, acute myocardial infarction, pulmonary edema
at the time of blood sampling, were taking calcium, ac-
tive vitamin D metabolites, bisphosphonates, teripara-
tide, or estrogens, or if they declined to provide
informed consent for the study.
Anthropometric analysis
Body weight was measured in light clothing and without
shoes to the nearest 0.5 kg, and body height was mea-
sured to the nearest 0.5 cm. Body mass index (BMI) was
calculated as the weight in kilograms divided by the
height in meters squared [18, 19].
Biochemical investigations
Fasting blood samples (approximately 5 ml) were imme-
diately centrifuged at 3000 g for 10 min. Serum levels of
blood urea nitrogen (BUN), creatinine (Cre), fasting glu-
cose, total cholesterol (TCH), triglycerides (TG), high-
density lipoprotein cholesterol (HDL-C), low-density
lipoprotein cholesterol (LDL-C), total calcium, and
phosphorus were measured using an autoanalyzer
(COBAS Integra 800, Roche Diagnostics, Basel,
Switzerland). [18, 19] Serum leptin concentrations were
determined using a commercially available enzyme im-
munoassay (EIA) (SPI-BIO, Montigny le Bretonneux,
France) [20]. Calculation of estimate glomerular filtra-
tion rate (GFR) was based on the Modification of Diet in
Renal Disease (MDRD) equation.
Carotid-femoral PWV (cfPWV) measurements
Measurement of cfPWV was performed using a pres-
sure tonometer to transcutaneously record the pressure
pulse waveform in the underlying artery (SphygmoCor
system, AtCor Medical, Australia), as previously de-
scribed [18, 19]. All measurements were performed in
the morning in the supine position after a minimum
10 min rest in a quiet, temperature-controlled room.
Recording were made simultaneously with an ECG sig-
nal, which provided an R-timing reference. Pulse wave
recordings were performed consecutively at two superfi-
cial artery sites (carotid-femoral segment). Integral soft-
ware was used to process each set of pulse wave and
ECG data to calculate the mean time difference between
R-wave and pulse wave on a beat-to-beat basis, with an
average of 10 consecutive cardiac cycles. The cfPWV
was calculated using the distance and mean time differ-
ence between the two recorded points. Quality indices, in-
cluded in the software, were set to ensure uniformity of
data. A cfPWV > 10 m/s was defined as high arterial stiff-
ness, and ≤ 10 m/s as low arterial stiffness according to
the European Society of Hypertension and the European
Society of Cardiology (ESH-ESC) 2013 Guidelines [5].
Statistical analysis
Normally distributed data were expressed as mean ±
standard deviation (SD), and comparisons were per-
formed using the Student’s independent t-test (two-
tailed). Data not normally distributed were expressed
as medians and interquartile ranges, and comparisons
were performed using the Mann–Whitney U test (TG,
fasting glucose, BUN, Cre, and leptin). Data expressed
as the number of patients were analyzed by the χ2 test.
Differences of leptin levels between numbers of oc-
cluded vessels was analyzed by the Kruskal-Wallis ana-
lysis of variance (AVONA) test. Variables that were
significantly associated with arterial stiffness were
tested for independence by multivariate logistic regres-
sion analysis (adapted factors: DM, HTN, age, SBP,
DBP, pulse pressure, and leptin). Data were analyzed
using SPSS for Windows (version 19.0; SPSS Inc.,
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Chicago, IL, USA). Values of P < 0.05 were considered
statistically significant.
Results
Demographic, biochemical, and clinical characteristics of
the 105 CAD patients are shown in Tables 1 and 2. A total
of 51 patients (48.6 %) had DM and 53 (50.5 %) HTN.
The use of drugs included angiotensin receptor blockers
(ARB; n = 28; 26.7 %), angiotensin-converting enzyme in-
hibitors (ACEi; n = 23; 21.9 %), calcium channel blockers
(CCB; n = 35; 33.3 %), β-blockers (n = 49; 46.7 %), statins
(n = 69; 65.7 %), and fibrate (n = 21; 20.0 %). Thirty-seven
patients (35.2 %) were defined as high arterial stiffness,
and this group of patients had a higher percentage of
DM (P = 0.001) and HTN (P = 0.010) as compared to
the low arterial stiffness group. There was no statisti-
cally significant difference in sex and use of ACEi, ARB,
β-blockers, CCB, statins, or fibrate between the two
groups. Age (P = 0.001), SBP (P < 0.001), DBP (P =
0.021), pulse pressure (P = 0.014), and serum leptin level
(P = 0.002) were higher in the high arterial stiffness
group compared with the low arterial stiffness group.
Fasting serum leptin levels based on the number of
stenotic coronary artery vessels are shown in Fig. 1.
There was a statistically significant difference between
the number of stenotic coronary artery vessels and
serum leptin levels (P < 0.001). Figure 2 showed two-
dimensional scattered plots of logarithmically trans-
formed leptin levels and cfPWV values among the 105
patients and revealed significantly positive correlation
(r = 0.390; P < 0.001).
Multivariate logistic regression analysis of the factors
significantly associated with arterial stiffness (age, DM,
HTN, SBP, DBP, pulse pressure, and leptin) showed that
leptin (P = 0.037), age (P = 0.002), and DM (P = 0.023)
were independent predictors of arterial stiffness
(Table 3).
Discussion
The results of this study showed that fasting leptin level
was higher in CAD patients with high arterial stiffness
than those with low arterial stiffness, and was an inde-
pendent predictor for the development of arterial
Table 1 Clinical variables of the 105 coronary artery disease patients
Characteristic All participants (n = 105) Low Arterial Stiffness (n = 68) High Arterial Stiffness (n = 37) P
Age (years)a 65.55 ± 9.19 63.31 ± 8.92 69.68 ± 8.19 0.001*
Height (cm)a 161.03 ± 8.19 161.59 ± 7.44 160.00 ± 9.43 0.345
Body weight (kg)a 67.80 ± 11.78 67.79 ± 12.39 67.80 ± 10.75 0.998
Body mass index (kg/m2)a 26.05 ± 3.39 25.82 ± 3.39 26.47 ± 3.40 0.357
cfPWV (m/s)a 9.37 ± 2.71 7.81 ± 1.32 12.25 ± 2.20 <0.001*
Systolic blood pressure (mmHg)a 132.10 ± 18.67 127.47 ± 16.18 140.59 ± 20.13 <0.001*
Diastolic blood pressure (mmHg)a 72.56 ± 10.32 70.85 ± 10.07 75.70 ± 10.16 0.021*
Pulse pressure (mmHg)a 59.53 ± 16.64 56.62 ± 14.22 64.89 ± 19.43 0.014*
Total cholesterol (mg/dl)a 165.98 ± 35.80 170.15 ± 37.45 158.32 ± 31.59 0.106
Triglyceride (mg/dl)b 117.00 (89.50–162.00) 116.00 (90.75–184.50) 117.00 (89.00–152.00) 0.351
HDL-C (mg/dl)a 45.33 ± 12.24 46.54 ± 12.15 43.11 ± 12.28 0.171
LDL-C (mg/dl)a 95.73 ± 26.58 97.37 ± 26.47 92.73 ± 26.87 0.396
Fasting glucose (mg/dl)b 111.00 (96.50–142.50) 107.00 (97.00–133.75) 114.00 (95.50–163.00) 0.509
Blood urea nitrogen (mg/dl)b 16.00 (13.00–19.00) 15.50 (13.00–18.00) 16.00 (13.00–21.50) 0.162
Creatinine (mg/dl)b 1.10 (0.90–1.30) 1.00 (0.90–1.20) 1.20 (0.90–1.40) 0.143
Glomerular filtration rate (ml/min)a 70.55 ± 20.36 73.10 ± 17.63 65.92 ± 24.13 0.085
Total calcium (mg/dl)a 9.13 ± 0.36 9.15 ± 0.36 9.08 ± 0.35 0.328
Phosphorus (mg/dl)a 3.52 ± 0.53 3.53 ± 0.55 3.49 ± 0.48 0.739
Ca × P product (mg2/dL2)a 32.12 ± 5.15 32.32 ± 5.39 31.74 ± 4.73 0.585
Leptin (ng/ml)b 6.58 (3.41–18.97) 5.50 (2.80–13.77) 13.60 (5.07–52.43) 0.002*
Data are expressed as mean ± standard deviation, except for triglycerides, fasting glucose, blood urea nitrogen, creatinine, C-reactive protein, and leptin, which are
expressed as median and interquartile range (IQR)
Abbreviations: cfPWV carotid-femoral pulse wave velocity, Ca × P product, calcium-phosphorus product, HDL-C, High density lipoprotein cholesterol, LDL-C Low
density lipoprotein cholesterol, iPTH Intact parathyroid hormone
aData were tested using Student’s t-test
bData were testing using Mann-Whitney U test
*P < 0.05 was considered statistically significant by Student’s t-test or Mann-Whitney U test
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stiffness. In addition, serum concentration of leptin cor-
related positively with the number of stenotic coronary
arteries.
Classic CV risk factors, including DM, hyperlipidemia,
elevated BMI, and smoking, have been implicated in ac-
celerating arterial stiffness. Aortic stiffness can affect
aortic function and reduce baroreceptor responsiveness,
and arterial stiffness one of the leading causes of in-
creased blood pressure [3, 21]. The pathophysiological
correlation between arterial stiffness and HTN is that
increased arterial stiffness reduces the lumen diameter
and leads to a premature return of the reflected wave in
late systole, resulting in increased pulse pressure and
SBP, and decreased DBP [22]. One systematic reviewed
has found that in approximately 90 % of studies, the
prognostic value of cfPWV may be independently re-
lated to a process of arterial ageing and elevation of BP,
and is probably unrelated to classical risk factors such as
sex, TCH, LDL-C, HDL-C, triglycerides, smoking, and
BMI [23]. Additionally, a population-based study showed
Table 2 Baseline characteristics of the 105 coronary artery disease patients
Characteristic Low Arterial Stiffness High Arterial Stiffness P
Gender Male 51 (75.0) 28 (75.7) 0.939
Female 17 (25.0) 9 (24.3)
Diabetes mellitus No 43 (63.2) 11 (29.7) 0.001*
Yes 25 (36.8) 26 (70.3)
Hypertension No 40 (58.8) 12 (32.4) 0.010*
Yes 28 (41.2) 25 (67.6)
Angiotensin-converting enzyme inhibitor No 53 (77.9) 29 (78.4) 0.959
Yes 15 (22.1) 8 (21.6)
Angiotensin-receptor blocker No 50 (73.5) 27 (73.0) 0.951
Yes 18 (26.5) 10 (27.0)
β-blocker No 36 (52.9) 20 (54.1) 0.913
Yes 32 (47.1) 17 (45.9)
Calcium-channel blocker No 48 (70.6) 22 (59.5) 0.248
Yes 20 (29.4) 15 (40.5)
Statin No 22 (32.4) 14 (37.8) 0.572
Yes 46 (67.6) 23 (62.2)
Fibrate No 50 (73.5) 30 (81.1) 0.385
Yes 14 (26.5) 7 (18.9)
Data are expressed as number (percentage), and were analysed with the chi-square test
*P < 0.05 was considered statistically significant
Fig. 1 Fasting leptin levels in patients with different numbers of
stenotic coronary vessels. Data were analysed by the Kruskal-Wallis
analysis of variance (AVONA) test
Fig. 2 Two-dimensional scatter-plots of carotid-femoral pulse wave
velocity and logarithmically transformed leptin levels among the 105
coronary artery disease patients
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that after adjusting for mean arterial pressure, age, and
gender impaired glucose tolerance and DM were inde-
pendently associated with central arterial stiffness [24].
Similarly, we found that CAD patients with high arterial
stiffness were older and had higher pulse pressure, SBP,
DBP, and a higher percentage had DM and HTN. Fur-
thermore, older age and DM were possible risk factors
for the development of arterial stiffness after adjusting
covariates.
Leptin is a peptide product of the obese gene, and is
predominantly secreted by white adipose tissue [10, 25].
In addition to have a physiological role of regulating hun-
ger and satiety, studies have shown an association between
leptin and CVD [7, 8]. Possible roles of leptin with respect
to the development of vascular lesions include stimulating
phosphorylation and activation of mitogen-activated pro-
tein kinases and phosphatidylinositol-3 kinase to increase
the proliferation and migration of vascular smooth muscle
cells, inducing endothelial dysfunction and enhancing the
effects of angiotensin II on BP via modulating the sympa-
thetic nervous system, and inducing formation of reactive
oxygen species by increasing fatty acid oxidation via pro-
tein kinase A activation in endothelial cells to contribute
to the development of arterial stiffness [14, 15, 26, 27].
Several cross-sectional studies which included aged, resist-
ant HTN, and healthy individuals showed that hyperlepti-
nemia was inversely associated with vasodilatation in
resistance arteries, and positively with PWV, and hence ar-
terial stiffness [28–30]. These studies, and our previous
study conducted in kidney transplantation recipients, re-
vealed a relationship between hyperleptinemia and arterial
stiffness measured by brachial-ankle PWV, and indicated
that leptin could have a role in the relationship between
abdominal adiposity and arterial stiffness, and have an im-
pact on the pathophysiology of macrovascular diseases
[28–31]. Moreover, in the current study we found that
hyperleptinemia correlated with cfPWV and was an inde-
pendent risk factor for the development of arterial stiff-
ness in patients with angiographically documented CAD.
In the current study, serum leptin correlated with the
total number of diseased coronary arteries. This finding
is similar with those of previous studies which revealed
that serum leptin plays an important role in the occur-
rence, severity, and extent of CAD [32–34]. Patients
with acute myocardial infarction have been reported to
have a trend for an increased serum leptin level with an
increasing number of diseased vessels [34]. In patients
with angiographically diagnosed coronary atheroscler-
osis, hyperleptinemia correlated positively with the de-
gree of vessel narrowing, the proportion abnormal
coronary artery segments, and the complexity of the ath-
erosclerotic lesions [32]. In diabetic patients, hyperlepti-
nemia was found to be a risk factor for the development
of CAD with an area under curve (AUC) of 0.62 (95 %
confidence interval [CI]: 0.54-0.7) in men and 0.71 (95 %
CI: = 0.6-0.83) in women by receiver operating charac-
teristic (ROC) curve analysis [33]. Based on these and
our studies [14, 15, 26, 27, 32–34], we believe that leptin
may serve as an adipose tissue derived intermediate for
the development of arterial stiffness, and a mediator in
the pathophysiology of macrovascular diseases.
Reports have shown that several types of medications
can affect arterial stiffness [35–40]. ACEi and ARB re-
duce central BP and augmentation index beyond the
expected degree from the BP lowering effects, which is
believed to be the result of reduction of oxidative stress
and inflammation, and vasodilatation through angio-
tensin II inhibition [35, 36]. Treating older hyperten-
sive patients with CCB resulted in a pronounced
reduction of central aortic pressure and augmentation
pressure as compared with placebo [35]. However,
studies of β-blockers on arterial stiffness showed a
lower effect on central BP decline compared with per-
ipheral BP [36, 37]. The effects of statins on the
reduction of aortic PWV are controversial, but recent
study showed that a low dose of atorvastatin exerted
beneficial effects on arterial stiffness and central aortic
pressure in patients with mild HTN and hypercholes-
terolemia [38, 39]. Treatment with the peroxisome
proliferator-activated receptor (PPAR) alpha agonist
fenofibrate resulted in significant reduction in the aug-
mentation index, PWV, and pro-inflammatory markers
in obese patients without glucose intolerance [40].
Compared to these previous studies, our study showed
that ACEi, ARB, β-blockers, CCB, statins, and fibrate
had no influences on arterial stiffness in CAD patients.
The limitation of this study is that there was a lack of
data regarding abdominal obesity to analyze the possible
influence on arterial stiffness in our patients and it was a
cross-sectional study with a limited number of CAD
patients conducted at a single center. Therefore, the
findings of this study should be confirmed by further
Table 3 Multivariate logistic regression analysis of factors correlated with arterial stiffness
Variables Odds Ratio 95 % Confidence Interval P
Leptin (ng/ml), per 1 ng/ml increase 1.026 1.002–1.051 0.037*
Age (years), per 1 year increase 1.105 1.036–1.179 0.002*
Diabetes mellitus, presence 3.369 1.185–9.576 0.023*
*P < 0.05 was considered statistically significant in the multivariate logistic regression analysis (adapted factors: diabetes mellitus, hypertension, age, systolic blood
pressure, diastolic blood pressure, pulse pressure, and leptin)
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longitudinal studies before a cause-effect relationship be-
tween serum leptin and arterial stiffness can be estab-
lished in the CAD population.
Conclusions
In conclusion, in this study which analyzing the role of
leptin in angiographically diagnosed CAD patients, we
found that serum leptin level correlated positively with
cfPWV and is a predictor for the development of arterial
stiffness. In addition, serum concentration of leptin cor-
related positively with the total number of stenotic cor-
onary arteries in our CAD patients.
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